Validation Processes

Regulatory Pathways for Biomarker Qualification

Posted on digi By digi

Biomarkers are vital tools in modern clinical trials, enabling early detection, risk stratification, pharmacodynamic monitoring, and surrogate endpoint development. However, before a biomarker can be used broadly in regulatory submissions, it must undergo a formal qualification process. Qualification provides regulators and industry with confidence that the biomarker is reliable, interpretable, and appropriate for a defined context of use (COU).
Click to read the full article.

Biomarkers and Companion Diagnostics, Validation Processes

Analytical vs Clinical Validation: Key Differences in Biomarker Qualification

Posted on digi By digi

Biomarkers are powerful tools in precision medicine, but before they can be qualified for regulatory use, they must undergo rigorous validation. This validation process is bifurcated into two critical arms: analytical validation and clinical validation. Understanding the difference is not just academic—it’s central to meeting global regulatory expectations from authorities like the FDA, EMA, and PMDA.
Click to read the full article.

Biomarkers and Companion Diagnostics, Validation Processes

Steps in Developing a Biomarker Validation Plan

Posted on digi By digi

Biomarkers are key instruments in translational medicine, enabling informed decision-making across drug development stages. Whether intended for diagnostic, prognostic, or monitoring use, biomarkers must be validated systematically before regulatory agencies will consider them qualified for use. Developing a comprehensive Biomarker Validation Plan (BVP) is the first structured step toward this goal.
Click to read the full article.

Biomarkers and Companion Diagnostics, Validation Processes

Statistical Methods for Biomarker Validation

Posted on digi By digi

In biomarker development, laboratory validation is only part of the picture. Without proper statistical validation, even the most analytically sound biomarkers may fail to demonstrate clinical utility. Regulatory agencies, including the FDA and EMA, emphasize the role of statistical methods in ensuring reproducibility, predictive accuracy, and confidence in biomarker-driven decisions.
Click to read the full article.

Biomarkers and Companion Diagnostics, Validation Processes

Pre-Analytical Variables in Biomarker Validation

Posted on digi By digi

Pre-analytical variables refer to all factors influencing a biological sample before it enters the analytical phase. These include sample collection, handling, processing, storage, and transport. In biomarker studies, especially within clinical trials, the reliability of analytical results is only as strong as the integrity of the pre-analytical phase.
Click to read the full article.

Biomarkers and Companion Diagnostics, Validation Processes

Common Pitfalls in Biomarker Assay Validation

Posted on digi By digi

Biomarker assay validation is a critical step in translating a laboratory discovery into a clinically meaningful diagnostic or therapeutic tool. Yet many validation attempts fail due to overlooked variables, misapplied methods, or regulatory gaps. Unlike pharmacokinetic (PK) bioanalytical validations, biomarker assays face more variability due to endogenous presence, matrix complexity, and lack of reference standards.
Click to read the full article.

Biomarkers and Companion Diagnostics, Validation Processes

Biomarker Validation Across Multiple Populations

Posted on digi By digi

In the era of precision medicine, validating biomarkers across multiple populations is essential for ensuring scientific robustness and regulatory acceptance. A biomarker validated in a homogeneous group may perform inconsistently when applied to genetically or demographically diverse cohorts. Factors like ethnicity, age, sex, genetic background, comorbidities, and environmental exposures significantly influence biomarker expression and utility.
Click to read the full article.

Biomarkers and Companion Diagnostics, Validation Processes

Cross-Validation in Multi-Center Trials

Posted on digi By digi

In large-scale clinical trials, especially those conducted globally or across multiple clinical sites, the reproducibility and consistency of biomarker measurements become critical. Cross-validation in multi-center trials ensures that a biomarker assay produces equivalent results regardless of the laboratory, technician, or instrument involved. This process is vital not only for scientific integrity but also for meeting regulatory expectations from agencies like the FDA and EMA.
Click to read the full article.

Biomarkers and Companion Diagnostics, Validation Processes

Case Study: Validating Biomarkers in Immunotherapy Trials

Posted on digi By digi

Immunotherapy has revolutionized cancer treatment, but its success hinges on identifying patients most likely to benefit. Biomarkers such as PD-L1 expression, tumor mutational burden (TMB), and microsatellite instability (MSI) are used to predict response to immune checkpoint inhibitors (ICIs). Validating these biomarkers in a clinical trial context is complex due to biological variability, assay challenges, and evolving regulatory expectations.
Click to read the full article.

Biomarkers and Companion Diagnostics, Validation Processes

FDA and EMA Requirements for Companion Biomarker Validation

Posted on digi By digi

Companion biomarkers are critical tools in the era of precision medicine, enabling targeted therapies by identifying patients most likely to benefit. Both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have established stringent requirements for validating these biomarkers, given their pivotal role in clinical decision-making. Validation is not just a scientific process—it is a regulatory mandate that ensures safety, accuracy, and therapeutic efficacy.
Click to read the full article.

Biomarkers and Companion Diagnostics, Validation Processes